SCHEMBL10163618

SCHEMBL10163618

CCc1cc2cc(C(C)(C)C)ccc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2C Q14957 1/20 0.40
CYP2A6 P11509 5/20 0.35
ADRB2 P07550 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ASIC3 Q9UHC3 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
TRPV1 Q8NER1 1/20 0.32
PPARG P37231 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NCOR2 Q9Y618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1755717 0.86 GRIN2C (0.40) GRIN2CCYP2A6ADRB2ALDH1A1HPGD
SCHEMBL19964771 0.84 CYP2A6 (0.53) CYP2A6ADRB2ALDH1A1HPGDALOX15
SCHEMBL2756695 0.81 ESR1 (0.35) GRIN2CCYP2A6ADRB2F2RL3TNF
SCHEMBL10132023 0.77 ALDH1A1 (0.39) ALDH1A1HPGDALOX15HSD17B10TDP1
SCHEMBL13464796 0.76 CYP2A6 (0.33) CYP2A6ADRB2HSD17B10ASIC3LOXL2
SCHEMBL27271308 0.76 PTPN22 (0.56)
SCHEMBL10222545 0.76 CYP2A6 (0.45) CYP2A6ADRB2ASIC3LOXL2CYP1A2
SCHEMBL6958993 0.76 CYP2A6 (0.50) CYP2A6ADRB2TDP1ASIC3LOXL2
SCHEMBL8279312 0.76 TSHR (0.38) CYP2A6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL23612352 0.74 BACE1 (0.41) CYP2A6ADRB2ALDH1A1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165320-A1 NOVEL AZABICYCLOHEXANES PANACEA BIOTEC LTD. (IN) 2012-06-28 US disclosed
US-7973181-B2 Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2011-07-05 US disclosed
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY HDAC1, HDAC3, HAT1 GRIN2C 811/4885CYP2A6 335/4885ADRB2 2882/4885
US-20120165320-A1 NOVEL AZABICYCLOHEXANES CYP3A43, UGT1A1, CYP3A4 GRIN2C 1474/4885CYP2A6 41/4885ADRB2 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.